Over the last few years, a population of myeloid derived cells that have immunosuppressive activity have been described (MDSCs). These MDSCs were initially found in the tumor microenvironment and are comprised primarily of monocytes/macrophages and dendritic cells. Cellerant has a research collaboration with Jos Domen, PhD (Children's Mercy Hospital, Kansas City, MO) to evaluate the potential of ex vivo expanded MDSCs to allow long-term solid organ transplantation of allogeneic tracheae or skin in mice. Unlike T-cell based cellular therapeutic products in development, Cellerant's MDSCs would not require MHC matching and would be an allogeneic 'off-the-shelf' product. This program is funded by a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant.